Figure 3 (Sevelamer Fig1)
Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 65862-921
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 65862-921). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 4 (Sevelamer Fig2)
This is a figure (Figure 3) that shows the percentage of patients who achieved a reduction in their serum phosphorus level (represented on the X-axis) from their baseline (mg/dL) at least as great as the value of the Y-axis. The graph compares the results between an active group and a control group. The percentage of patients who improved or worsened in their phosphorous levels are also represented in the graph.*
Package Label-principal Display Panel – 800 mg (30 Tablets Bottle) (Sevelamer Fig3)
Sevelamer Fig4
Sevelamer Carbonate Tablets by Aurobindo Pharma USA, Inc. contains Sevelamer carbonate 800 mg as an active ingredient. These tablets are available in a package of 30 tablets and are for Rx use only. Inactive ingredients such as acetylated monoglycerides, ammonium hydroxide, black iron oxide, colloidal silicon dioxide, crospovidone, glyceryl dibehenate, hydroxypropyl cellulose, hypromellose, mannitol, propylene glycol, shellac glaze, and tal are also included. The package insert contains usual dosage information. These tablets should be stored in a tight container between 20-25°C to protect them from moisture. The given code is TS/IDRUGS/22/2009, and the printed area is 45x15 mm.*
Chemical Structure (Sevelamer Str)
This is a chemical structure diagram of Sevelamer Carbonate, a medication used to lower high levels of phosphorus in patients with chronic kidney disease. The diagram illustrates the molecular structure of the compound, including the number of primary amine groups (a and b) and the number of crosslinking groups (e=1) that contribute to its extended polymer network.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
